-
DMD treatment WVE-N531 boosts dystrophin: Interim trial data
Treatment with exon 53-skipping therapy WVE-N531 led to significant increases in muscle dystrophin levels along
-
2024 Rev It Up 5k Raises $27,000 for PPMD
The Rev It Up 5K presented by Mitsubishi Electric Automotive America held their 4th annual
-
PPMD Hosts Meeting Exploring the Case for Cardiac Transplantation in Duchenne
As part of our ongoing Cardiac Initiative, PPMD is proud to host the upcoming professional
-
Capricor to seek deramiocel’s FDA approval for DMD heart disease
Capricor Therapeutics will soon begin filing an application seeking U.S. approval of its cell therapy
-
PPMD Joins Duchenne Parent Project aps Respiratory International Professional Care Meeting
Parent Project Muscular Dystrophy (PPMD) is pleased to announce our participation in the upcoming “Respiratory
-
MDA Engage offers neuromuscular disease updates, connections
The Muscular Dystrophy Association (MDA) is providing neuromuscular disease (NMD) patients and their families with
-
Catch Up on Our PPMD Together Event in Seattle, Washington
This past weekend, PPMD convened over 100 attendees at our PPMD Together event in Seattle,
-
Examples of ableism I’ve encountered in life with FSHD
I’ve been disabled for over 50 years, and I spent over 30 years working with
-
Positive Interim Data from Wave Life Sciences Exon 53 Skipping Program
CureDuchenne is pleased to communicate that Wave Life Sciences announced positive interim data from the
-
Thanks to You PPMD Continues Forward in All Areas of Support
As we celebrate PPMD’s Duchenne Action Month inspired by World Duchenne Awareness Day, we are
